Vaccinia immune globulin, human, is only made available by a doctor's prescription, and comes in parenteral and injection forms, the latter in the US and Canada. It is used to treat infections caused by the vaccinia virus. It has been given the brand name VIGIV and can treat multiple conditions.
This medication was developed in the 1960s with a plan to ameliorate the side effects that emerged following a smallpox immunization process. The original composition contained high levels of protein aggregates and was thus administered intramuscularly, and is unavailable at the moment. VIG, human, is the only available treatment for people who might suffer complications associated with vaccinia vaccination.
Preparation of VIGIV involves a collection of plasma from healthy, screened donors who have high amounts of an anti-vaccinia antibody that meets the minimum potency requirements. Each plasma used in the manufacture of VIGIV is tested for hepatitis B virus, hepatitis C virus, surface antigen, and HIV, using the FDA licensed serological tests.
VIGIV is considered a valuable insurance which should be reserved in case a patient receives an experimental vaccine that involves a vaccinia carrier virus, or as a viable complications manager for the smallpox vaccine in case a bioterrorism threat is imminent.
VIG, human, is used to treat or modify the listed conditions, which are complications that can arise after a smallpox vaccination:
Along with its essential needs, VIGIV may cause a number of unwanted effects. While not all these side effects will manifest, if they do medical attention may be required. Some of the side effects of VIGIV include:
Some of the side effects do not necessarily need medical attention, as they will probably disappear once the body adjusts to the medicine. A medical practitioner is in the right place to inform the patient of ways to alleviate the side effects. Visit a health care professional for any questions or a side effect is bothering you.
This is not a complete list of all side effects, and you may experience others. If you see or experience other forms of side effects, contact a doctor for further medical advice, or report it to FDA at 1-800-FDA-1088.
Dosage depends on individual patients and, therefore, is different from patient to patient. Follow your doctor's instructions as indicated on the label. If your doctor gives you a different dosage, do not change it unless the doctor tells you to. Listed below is only the average dose of this medicine.
How much you take also depends on the strength of the medicine. Similarly, the time between doses, the number of prescriptions taken each day and the duration you have to take your medicine for depends wholly on the medical challenge you are experiencing that necessitates the use of this medication.
The initial dose should be 100 mg/kg, which is 2mL/kg by IV infusion. This should be injected over about 70 minutes. If the patient is unresponsive to a lower dose, increase it and give 200 mg/kg or 500 mg/kg by IV infusion.
The infusion rate should be conducted in this manner: 1 mL/kg/hour for the first 30 minutes. Subsequently, 2 mL/kg/hour for the next 30 minutes and finally 3 mL/kg/hour for the remainder solution.
The infusion should be temporarily interrupted or slowed in case of minor adverse reactions, such as flushing. Other forms of severe adverse reactions, such as anaphylaxis or high blood pressure, can occur, and should be mediated by halting infusion and administering epinephrine, with or without diphenhydramine.
Currently, VIG interacts moderately with a total of 21 drugs (54 brand and generic names) and thus should be monitored closely. Below is a comprehensive list of the drugs:
The FDA has assigned VIG to pregnancy category C. No adequate controlled data exist showing any risks to pregnant women.
Similarly to pregnancy, no adequate data exists to determine the risks of using the drug while breastfeeding. Mothers should weigh the benefits against the potential dangers of the drug before using it.
Administration of VIGIV has been associated with antiglobulin hemolysis. Thus, one should monitor for any signs of hemolytic anemia which might occur due to high doss either administered singly or over an extended period.
Inform your doctor of any allergies against this or any other medication. Further, tell your doctor of any allergic reactions to food, preservatives, dyes or animals.
There is insufficient data that compares this drug's function in older adults with that among young people. Most medicines have not been studied in older people, and, therefore, one cannot conclude on the drug causing different side effects among them.
Renal failure is a likely occurrence when using VIG. People predisposed to it include:
VIGIV should be stored at moderately low temperatures of between 2 and 8 degrees Celsius or 35.6 and 46.4 degrees Fahrenheit. Intravenous infusion should begin within six hours after entering the vial.
Vaccinia immune globulin, human (VIGIV), is a sterile liquid immunoglobin (Ig) used to treat infections caused by the vaccinia virus. It is only available only with a doctor's prescription and cannot be taken at free will. Each lot of VIGIV contains anti-vaccinia virus antibody, which is collected from people who meet the minimum potency threshold. This medicine is used to treat an array of conditions, including aberrant infections and vaccinia infections.
Before deciding to use the drug, weigh the risks with the benefits. This decision shall be made at the discretion of your doctor. The dosage will depend on the type of condition being treated and the weight of the individual. All these are factors your doctor will consider before giving the appropriate dose.
VIGIV, an immune globulin medicine, has several side effects ranging from general body pains to changing of skin or lip color. Get in touch with your doctor immediately you observe any side effects. The drug interacts with several other medicines, it is thus essential to discuss the drug use with a healthcare professional before using it. As indicated, the drug should be kept at low temperatures.